Humabs launches with preclinical infection MAbs to partner
This article was originally published in Scrip
Humabs BioMed has been launched as an independent company based in Switzerland, some seven years after its formation as an incubator for two platform antibody technologies. The firm, which received early angel investment from Dr Bill Rutter, its chairman and former chairman of Chiron, was originally established as a Delaware-incorporated company, but is now fully transferred to Switzerland, where it conducts its work in close co-operation with the Institute for Research in Biomedicine (IRB) in Bellinzona, Switzerland.
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.